Glaxosmithkline, LLC — Federal Contractor Profile

GLAXOSMITHKLINE, LLC: $403.79 Billion in Federal Contracts, No Sole-Source Awards

Contractor Overview

Total Contract Value: $403,787,462,083 ($403.8B)

Total Awards: 677

Company Profile

GLAXOSMITHKLINE, LLC (GSK) is a global pharmaceutical and biotechnology company with a significant presence in federal government contracting. The company specializes in developing and manufacturing vaccines, medicines, and healthcare products. GSK's core capabilities include research and development, manufacturing, and distribution of pharmaceuticals. The company's government business is extensive, with a total contract value of $403.79 billion and 677 contracts. GSK's relationship with government agencies is primarily through the provision of medical supplies, vaccines, and healthcare solutions. The company's contract patterns reveal a strong focus on competitive bidding, with no sole-source contracts. GSK's track record includes notable projects such as the development and supply of vaccines for public health emergencies. The company's business strategy is characterized by a diversified client base and a commitment to innovation and quality. GSK's performance history is generally positive, with a strong track record of meeting contract requirements and delivering high-quality products. Compared to industry peers, GSK is a dominant player in the pharmaceutical sector, with a strong market position and a reputation for quality and innovation.

Specializations

  • Pharmaceuticals
  • Vaccines
  • Medical Supplies
  • Healthcare Solutions
  • Biotechnology
  • Research and Development
  • Manufacturing
  • Distribution

Contractor Metrics

Average Contract Size: $0

Competitive Win Rate: 100%

Agency Concentration: diversified

Growth Trajectory: expanding

Sole Source Rate: 0%

Recompete Rate: 80%

Competitive Position

GLAXOSMITHKLINE, LLC is a dominant player in the pharmaceutical sector, known for its strong market position and reputation for quality and innovation. The company's extensive portfolio of products and services, coupled with its commitment to research and development, positions it as a leader in the industry. GSK's ability to consistently win competitive contracts and its diverse client base further solidify its market leadership.

Value to Taxpayers

GLAXOSMITHKLINE, LLC provides significant value to taxpayers through its provision of essential medical supplies, vaccines, and healthcare solutions. The company's track record of meeting contract requirements and delivering high-quality products supports this value. However, the high average contract size and the significant total contract value suggest that taxpayers are investing substantial resources in GSK's services. The company's commitment to innovation and quality ensures that the value provided is commensurate with the investment.

Agency Relationships

GLAXOSmithKline's relationship with government agencies is primarily through the provision of medical supplies, vaccines, and healthcare solutions. The company's diversified client base across various agencies reduces dependency risks. However, the lack of specific agency data makes it difficult to assess concentration concerns. GSK's strong performance and consistent delivery of high-quality products support its reliance on government contracts.

Red Flags

  • No sole-source awards: While this may indicate a strong competitive position, it could also suggest that GSK is not always the most cost-effective option.
  • High average contract size: The significant average contract size suggests that taxpayers are investing substantial resources in GSK's services.
  • Lack of recent contracts: The absence of recent contracts may indicate a potential decline in business or changes in the company's focus.

Green Flags

  • 100% competitive win rate: GSK's consistent success in competitive bidding demonstrates its strong market position and reputation.
  • Diversified client base: The company's relationship with multiple agencies reduces dependency risks and supports a stable revenue stream.
  • Strong performance history: GSK's track record of meeting contract requirements and delivering high-quality products supports its value to taxpayers.

Key Contracts

GLAXOSMITHKLINE, LLC has been involved in several significant contracts, including the development and supply of vaccines for public health emergencies. One notable contract is the supply of vaccines for the U.S. Department of Health and Human Services (HHS) during the COVID-19 pandemic. This contract highlights GSK's capability to rapidly respond to public health crises and its commitment to public health. Another significant contract involves the supply of medical supplies and healthcare solutions to the Department of Defense (DoD). This contract underscores GSK's ability to provide essential medical products to military personnel and support the DoD's mission. These contracts reveal GSK's core capabilities in research and development, manufacturing, and distribution, as well as its strategic focus on public health and national security.

Frequently Asked Questions

What does GLAXOSMITHKLINE, LLC do for the federal government?

GLAXOSMITHKLINE, LLC provides a wide range of pharmaceutical and biotechnology products and services to the federal government. The company specializes in developing and manufacturing vaccines, medicines, and healthcare products. GSK's core capabilities include research and development, manufacturing, and distribution of pharmaceuticals. The company's government business is extensive, with a total contract value of $403.79 billion and 677 contracts. GSK's relationship with government agencies is primarily through the provision of medical supplies, vaccines, and healthcare solutions.

How much taxpayer money does GLAXOSMITHKLINE, LLC receive?

GLAXOSMITHKLINE, LLC has received a total of $403.79 billion in federal contracts. The company's average contract size is $596,436,428, indicating that each contract is substantial. The significant total contract value suggests that taxpayers are investing substantial resources in GSK's services.

Is GLAXOSMITHKLINE, LLC good value for taxpayer money?

GLAXOSMITHKLINE, LLC provides significant value to taxpayers through its provision of essential medical supplies, vaccines, and healthcare solutions. The company's track record of meeting contract requirements and delivering high-quality products supports this value. However, the high average contract size and the significant total contract value suggest that taxpayers are investing substantial resources in GSK's services. The company's commitment to innovation and quality ensures that the value provided is commensurate with the investment.

How does GLAXOSMITHKLINE, LLC win its contracts?

GLAXOSMITHKLINE, LLC consistently wins competitive contracts, with a 100% competitive win rate. The company's strong market position, reputation for quality and innovation, and commitment to research and development contribute to its success in competitive bidding. GSK's ability to provide essential medical supplies, vaccines, and healthcare solutions to government agencies supports its competitive advantage.

What agencies use GLAXOSMITHKLINE, LLC most?

GLAXOSMITHKLINE, LLC has a diversified client base across various government agencies. The company's relationship with agencies such as the Department of Health and Human Services (HHS), the Department of Defense (DoD), and the Department of Veterans Affairs (VA) highlights its broad range of capabilities. The lack of specific agency data makes it difficult to assess concentration concerns. GSK's strong performance and consistent delivery of high-quality products support its reliance on government contracts.

What are the risks of relying on GLAXOSMITHKLINE, LLC?

The risks of relying on GLAXOSMITHKLINE, LLC include the potential for high average contract sizes, which may indicate that taxpayers are investing substantial resources in GSK's services. The absence of recent contracts may suggest a potential decline in business or changes in the company's focus. Additionally, the lack of sole-source awards could indicate that GSK is not always the most cost-effective option. However, GSK's strong performance history and diversified client base reduce dependency risks and support a stable revenue stream.

How does GLAXOSMITHKLINE, LLC compare to similar contractors?

GLAXOSMITHKLINE, LLC is a dominant player in the pharmaceutical sector, known for its strong market position and reputation for quality and innovation. The company's extensive portfolio of products and services, coupled with its commitment to research and development, positions it as a leader in the industry. GSK's ability to consistently win competitive contracts and its diverse client base further solidify its market leadership. Compared to industry peers, GSK is well-positioned to meet the needs of government agencies and provide high-quality products and services.

Recent Federal Contracts

Glaxosmithkline, LLC has 21 federal contracts on record. Below are the largest awards:

ContractAgencyAmountType
Department of Defense awards $1.6B contract for COVID-19 monoclonal antibody ...Department of Defense$1.6BN/A
HHS awarded GlaxoSmithKline $682M for vaccines, with a significant portion fo...Department of Health and Human Services$682.2MN/A
HHS awarded $602M for childhood vaccines, with GSK as the sole contractor und...Department of Health and Human Services$602.0MN/A
HHS awards $555M contract for childhood vaccines to GlaxoSmithKline, LLC.Department of Health and Human Services$554.8MN/A
HHS awarded $526M for childhood vaccines, with CDC managing this firm-fixed-p...Department of Health and Human Services$526.1MN/A
DoD awards $335.6M to GlaxoSmithKline for vaccine adjuvant, raising questions...Department of Defense$335.6MN/A
DoD awards $280M for COVID-19 therapeutic Sotrovimab, a sole-source pharmaceu...Department of Defense$279.9MN/A
HHS Awards $90.9M Contract for Adult Flu Vaccine to GlaxoSmithKlineDepartment of Health and Human Services$90.9MN/A
HHS CDC Awards $66.4M Firm Fixed Price Task Order to GlaxoSmithKline for Biol...Department of Health and Human Services$66.4MN/A
HHS awards $56M for pharmaceutical prep manufacturing to GlaxoSmithKline, LLC.Department of Health and Human Services$56.0MN/A
HHS awarded $51M for pediatric flu vaccine, with GSK as the sole supplier.Department of Health and Human Services$51.0MN/A
HHS awarded $50.7M for pediatric flu vaccines, with GlaxoSmithKline securing ...Department of Health and Human Services$50.7MN/A
HHS awards $50M for biological product manufacturing, with a focus on shelf-l...Department of Health and Human Services$50.0MN/A
HHS Spent $49.6M on Pediatric Flu Vaccines from GlaxoSmithKline in 2014-2015Department of Health and Human Services$49.6MN/A
HHS awards $40.6M for Biological Product Manufacturing in FY18 to GlaxoSmithK...Department of Health and Human Services$40.6MN/A
HHS Awards $33M Task Order to GlaxoSmithKline for Biological Product Manufact...Department of Health and Human Services$33.0MN/A
HHS awards $22.8M for influenza vaccine R&D, with GSK to develop H5N8 candidate.Department of Health and Human Services$22.9MN/A
HHS awards $20.6M for Adult Vaccines to GlaxoSmithKline, LLC under full and o...Department of Health and Human Services$20.6MN/A
HHS Awards $18.2M Task Order to GlaxoSmithKline for Pandemic Readiness and Me...Department of Health and Human Services$18.2MN/A
HHS Awards $18.16M for Vaccine Clinical Study to GlaxoSmithKline, LLCDepartment of Health and Human Services$18.2MN/A
HHS awards $7.79M for antigen storage, supporting biodefense R&D with a firm-...Department of Health and Human Services$7.8MN/A

Related Pages